Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read More ›

Subanalysis strongly supports the use of isatuximab plus carfilzomib and dexamethasone regardless of prior lines of therapy or refractory status to lenalidomide and bortezomib. Read More ›

Integrating a pharmacist into the care team can have substantial clinical and financial benefits in the setting of relapsed/refractory multiple myeloma and anti-CD38 antibodies. Read More ›

Carfilzomib plus dexamethasone and daratumumab show improved responses compared with carfilzomib plus dexamethasone in patients with relapsed/refractory multiple myeloma regardless of cytogenetic risk. Read More ›

The addition of autologous stem-cell transplantation to triplet induction—lenalidomide, bortezomib, and dexamethasone—plus lenalidomide maintenance until progression greatly improved progression-free survival. Read More ›

Patients with multiple myeloma require high levels of complex information regarding this complex disease and its treatments. Read More ›

Isatuximab added to carfilzomib and dexamethasone showed improved efficacy and safety versus carfilzomib and dexamethasone alone in East Asian patients with multiple myeloma. Read More ›

Improved survival was seen in women with elevated body mass index versus men among patients newly diagnosed with multiple myeloma. Read More ›

Ciltacabtagene autoleucel shows benefit in patients with multiple myeloma who experience early relapse. Read More ›

Multiple Myeloma is a complex disease that can significantly affect the health-related quality of life of patients. These quality-of-life issues should be considered when assessing treatment patterns. Read More ›